167 related articles for article (PubMed ID: 24589268)
1. Alterations of the arginine metabolome in sickle cell disease: a growing rationale for arginine therapy.
Morris CR
Hematol Oncol Clin North Am; 2014 Apr; 28(2):301-21. PubMed ID: 24589268
[TBL] [Abstract][Full Text] [Related]
2. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Okam MM; Ebert BL
Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
[TBL] [Abstract][Full Text] [Related]
3. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice.
Taylor CM; Kasztan M; Sedaka R; Molina PA; Dunaway LS; Pollock JS; Pollock DM
Am J Physiol Regul Integr Comp Physiol; 2021 May; 320(5):R630-R640. PubMed ID: 33624556
[TBL] [Abstract][Full Text] [Related]
5. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?
Morris CR; Morris SM; Hagar W; Van Warmerdam J; Claster S; Kepka-Lenhart D; Machado L; Kuypers FA; Vichinsky EP
Am J Respir Crit Care Med; 2003 Jul; 168(1):63-9. PubMed ID: 12626350
[TBL] [Abstract][Full Text] [Related]
6. [How I treat ... sickle cell anemia: current therapies].
Rezaei Kalantari H
Rev Med Liege; 2001 Oct; 56(10):671-5. PubMed ID: 11765575
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea.
Nahavandi M; Tavakkoli F; Wyche MQ; Perlin E; Winter WP; Castro O
Br J Haematol; 2002 Dec; 119(3):855-7. PubMed ID: 12437671
[TBL] [Abstract][Full Text] [Related]
8. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
[TBL] [Abstract][Full Text] [Related]
9. Use of hydroxyurea in children with sickle cell disease: what comes next?
Ohene-Frempong K; Smith-Whitley K
Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
[TBL] [Abstract][Full Text] [Related]
10. An update on arginine in sickle cell disease.
Benites BD; Olalla-Saad ST
Expert Rev Hematol; 2019 Apr; 12(4):235-244. PubMed ID: 30855194
[TBL] [Abstract][Full Text] [Related]
11. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.
Ma Q; Wyszynski DF; Farrell JJ; Kutlar A; Farrer LA; Baldwin CT; Steinberg MH
Pharmacogenomics J; 2007 Dec; 7(6):386-94. PubMed ID: 17299377
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea and sickle cell disease: a chance for every patient.
Weiner DL; Brugnara C
JAMA; 2003 Apr; 289(13):1692-4. PubMed ID: 12672739
[No Abstract] [Full Text] [Related]
13. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
14. [Hydroxyurea and other agents stimulating synthesis of fetal hemoglobin].
de Montalembert M
Pathol Biol (Paris); 1999 Jan; 47(1):55-8. PubMed ID: 10081780
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea for sickle cell anemia.
Naina HV; Harris S
N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283
[No Abstract] [Full Text] [Related]
16. Hydroxyurea for children with sickle cell disease.
Heeney MM; Ware RE
Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
[TBL] [Abstract][Full Text] [Related]
17. Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.
Little JA; Hauser KP; Martyr SE; Harris A; Maric I; Morris CR; Suh JH; Taylor J; Castro O; Machado R; Kato G; Gladwin MT
Eur J Haematol; 2009 Apr; 82(4):315-21. PubMed ID: 19215288
[TBL] [Abstract][Full Text] [Related]
18. Sickle cell disease: role of reactive oxygen and nitrogen metabolites.
Wood KC; Granger DN
Clin Exp Pharmacol Physiol; 2007 Sep; 34(9):926-32. PubMed ID: 17645642
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
Anderson N
Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
[TBL] [Abstract][Full Text] [Related]
20. The genomics of new drugs in sickle cell disease.
Makis AC; Hatzimichael EC; Stebbing J
Pharmacogenomics; 2006 Sep; 7(6):909-17. PubMed ID: 16981849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
